EGFR and non-small cell lung carcinoma: Finally, reducing the number of TAMs in the TME of EGFR-mutant NSCLC, either by inhibiting TAM recruitment or depleting TAMs, may represent a promising strategy to overcome resistance to EGFR-TKIs.